載入中
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
一般交易時段
US$97.11
−US$4.63 · -4.55%
盤中時間採用ET。市場資料可能有所延遲。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日內區間
目前US$97.11
52週區間
目前US$97.11
盤中時間採用ET。市場資料可能有所延遲。
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
日內區間
目前US$97.11
52週區間
目前US$97.11
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.06億 USD | 3.64億 USD | 3.05億 USD | 2.45億 USD | 1.88億 USD |
| 銷貨成本 | 1.25億 USD | 8574.2萬 USD | 6557.3萬 USD | 5512.6萬 USD | 4415.2萬 USD |
| 毛利 | 4.82億 USD | 2.78億 USD | 2.4億 USD | 1.9億 USD | 1.44億 USD |
| 研究與開發 | 7.71億 USD | 5.98億 USD | 5.71億 USD | 3.98億 USD | 2.73億 USD |
| 銷售、一般及管理費用 | 7.01億 USD | 4.61億 USD | 3.45億 USD | 2.66億 USD | 2.34億 USD |
| 營業費用 | 16.58億 USD | 11.56億 USD | 9.49億 USD | 6.48億 USD | 5.19億 USD |
| 利息收入 | 6065.6萬 USD | 5330.7萬 USD | 4213.2萬 USD | 1108.1萬 USD | 17.4萬 USD |
| 利息支出 | 8379.5萬 USD | 8491.3萬 USD | 8169.4萬 USD | 2644.6萬 USD | 4047.3萬 USD |
| 折舊和攤銷 | 1645萬 USD | 1101.3萬 USD | 1057.9萬 USD | 1033.1萬 USD | 1418.2萬 USD |
| 營業利益 | −11.77億 USD | −8.78億 USD | −7.1億 USD | −4.57億 USD | −3.75億 USD |
| 淨利 | −12.77億 USD | −9.14億 USD | −7.5億 USD | −4.82億 USD | −4.35億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$197
上漲空間 102.86%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2011年3月3日 | 1:10 | — | — |
股票分割 | 2000年7月31日 | 1:4 | — | — |
已生效 2011年3月3日
1:10
已生效 2000年7月31日
1:4
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8.4億0.04%2.3兆 USD0.03%US$379.55-0.39%
Vanguard Extended Market ETFVXF3.07億0.32%954億 USD0.05%US$231.62-0.80%
Vanguard Morningstar Small-Cap ETFVB3.04億0.16%1853億 USD0.03%US$285.45-0.53%
Vanguard Morningstar Mid-Cap ETFVO2.86億0.13%2264億 USD0.03%US$80.025-0.14%
Vanguard Morningstar Growth ETFVUG2.18億0.06%3846億 USD0.03%US$91.925-0.54%
Vanguard Morningstar Small-Cap Growth ETFVBK1.74億0.38%447億 USD0.05%US$338.95-0.96%
iShares Biotechnology ETFIBB1.66億1.59%104.01億 USD0.44%US$196.98-3.13%
State Street SPDR S&P Biotech ETFXBI1.26億1.23%100.75億 USD0.35%US$146.14-2.72%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Mid-Cap ETFVOVanguard Morningstar Growth ETFVUGVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBState Street SPDR S&P Biotech ETFXBIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
